| Περίληψη: |
Diabetes mellitus is associated with significant cardiovascular and haematological disturbances. This study evaluated the effects of prazosin and propranolol, alone and combined with glibenclamide, on haematological parameters and electrocardiographic (ECG) indices in streptozotocin (STZ)-induced diabetic Wistar rats. Thirty-five male Wistar rats were randomly assigned to seven groups (n = 5): Normal Control (NC), Diabetic (Diab), Diabetic + Glibenclamide (Diab + Glib; 5 mg/kg/day), Diabetic + Prazosin (Diab + Prz; 0.5 mg/kg/day), Diabetic + Prazosin + Glibenclamide (Diab + Prz + Glib), Diabetic + Propranolol (Diab + Prop; 10 mg/kg/day), and Diabetic + Propranolol + Glibenclamide (Diab + Prop + Glib). STZ (60 mg/kg, i.p.) induced a type 1-like diabetes model. Drugs were given orally for three weeks. Data were analysed by one-way ANOVA with Dunnett's post-hoc test versus NC. Significant inter-group differences were found in white blood cell (WBC) count (F = 3.11, p = 0.021), lymphocyte (F = 2.90, p = 0.028), neutrophil (F = 4.03, p = 0.006), monocyte (F = 4.97, p = 0.002), and eosinophil percentages (F = 3.01, p = 0.024). Dunnett's test identified significantly elevated neutrophil percentage in Diab + Prop versus NC (35.60 ± 1.03% vs. 26.00 ± 1.22%; p < 0.05), attenuated by glibenclamide co-administration. Packed cell volume (PCV), haemoglobin (Hb), red blood cell count (RBC), platelet count, and erythrocyte sedimentation rate (ESR) were preserved across all groups. Heart rate (HR; F = 3.38, p = 0.022) and R-wave amplitude (F = 3.76, p = 0.014) differed significantly; Diab + Prop significantly reduced HR versus NC (226 ± 6 vs. 256 ± 3 beats/min; p < 0.05). No significant QT or corrected QT interval (QTc) prolongation was observed. Propranolol, but not prazosin, caused leucocyte differential shifts and reduced cardiac rate in STZ-diabetic rats, both attenuated by glibenclamide. Red cell indices, platelet counts, and ECG conduction intervals were preserved, indicating no haematological toxicity or pro-arrhythmic liability for these drug combinations. [ABSTRACT FROM AUTHOR] |